Literature DB >> 17384909

Recurrent bile duct stricture: causes and long-term results of surgical management.

Biju Pottakkat1, Sadiq S Sikora, Ashok Kumar, Rajan Saxena, Vinay K Kapoor.   

Abstract

BACKGROUND/
PURPOSE: The management of recurrent bile duct strictures is a challenge for surgeons. This study reports the experience of revision surgery in patients referred following the failure of primary repair, and compares the outcome with that in patients who underwent management of recurrent stricture following primary repair at our institution.
METHODS: Over a period of 15 years, 300 patients with postcholecystectomy benign biliary stricture underwent surgical repair at our institution; 36 patients (12%) were referred after a failed primary repair.
RESULTS: In 25 (69%) patients, the primary repairs were done at peripheral hospitals. Twelve (33%) had had an early repair, at the time of cholecystectomy while 24 (67%) had a delayed repair at a later date; 83% and 67% of the patients who had undergone early and delayed repair, respectively, had not had a preoperative cholangiogram. Primary repairs performed were a bilioenteric anastomosis (22; 61%) or an end-to-end bile duct repair (14; 39%). Twenty-seven (75%) patients presented within 90 days after the primary repair, and the median interval to recurrent symptoms was 45 days (range, 1 day to 6.1 years). The median delay in referral after the development of symptoms of restricture was 175 days (range, 30 days to 22 years). Twenty-three (64%) patients had high strictures (Bismuth types III-V). All patients underwent a Roux-en-Y hepaticojejunostomy. At a median follow-up of 37 months (range, 12-144 months), 33 of 35 evaluable patients (94%) with recurrent stricture had an excellent/good outcome compared to 223 of 242 evaluable patients (92%) who had had their primary repair at our institution. Ten (4%) patients had a poor result following primary repair at our center. There was a significant difference in the stricture repair-to-recurrence interval between those patients referred to us with recurrent strictures and those who failed after primary repair at our institution (median interval, 1.5 vs 20 months; P = 0.001)
CONCLUSIONS: Patients referred with recurrent strictures had had their primary repair at peripheral settings; the failures were technical, presenting early (median, 1.5 months) with recurrent symptoms, compared to findings in patients with recurrent strictures following primary repair at our center. The long-term outcome following the repair of the primary and the recurrent strictures was no different in our experience.

Entities:  

Mesh:

Year:  2007        PMID: 17384909     DOI: 10.1007/s00534-006-1126-0

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Surg        ISSN: 0944-1166


  12 in total

Review 1.  Postcholecystectomy bile duct injury and its sequelae: pathogenesis, classification, and management.

Authors:  Kishore G S Bharathy; Sanjay S Negi
Journal:  Indian J Gastroenterol       Date:  2013-09-03

2.  Effect of tamoxifen on fibrosis, collagen content and transforming growth factor-β1, -β2 and -β3 expression in common bile duct anastomosis of pigs.

Authors:  Orlando Hiroshi Kiono Siqueira; Karen Jesus Oliveira; Angela Cristina Gouvêa Carvalho; Antonio Claudio Lucas da Nóbrega; Renata Frauches Medeiros; Bruno Felix-Patrício; Fábio Otero Áscoli; Beni Olej
Journal:  Int J Exp Pathol       Date:  2017-12-04       Impact factor: 1.925

3.  Factors predicting failure following high bilio-enteric anastomosis for post-cholecystectomy benign biliary strictures.

Authors:  Biju Pottakkat; Ranjit Vijayahari; Anand Prakash; Rajaneesh Kumar Singh; Anu Behari; Ashok Kumar; Vinay K Kapoor; Rajan Saxena
Journal:  J Gastrointest Surg       Date:  2010-06-30       Impact factor: 3.452

4.  Biliary cirrhosis and sepsis are two risk factors of failure after surgical repair of major bile duct injury post-laparoscopic cholecystectomy.

Authors:  L Sulpice; S Garnier; M Rayar; B Meunier; K Boudjema
Journal:  Langenbecks Arch Surg       Date:  2014-05-06       Impact factor: 3.445

5.  Liver transplantation for iatrogenic bile duct injuries sustained during cholecystectomy.

Authors:  Pietro Addeo; Anne-Catherine Saouli; Bernard Ellero; Marie-Lorraine Woehl-Jaegle; Elie Oussoultzoglou; Edoardo Rosso; Manuela Cesaretti; Philippe Bachellier
Journal:  Hepatol Int       Date:  2013-07-31       Impact factor: 6.047

6.  Outcome of reoperative surgery for late failure of postcholecystectomy bile duct injury repair.

Authors:  Sukanta Ray; Sujan Khamrui; Zuber Ansari; Arunesh Gupta; Suman Das; Jayanta Biswas
Journal:  Updates Surg       Date:  2022-07-16

7.  Reoperative surgery after repair of postcholecystectomy bile duct injuries: is it worthwhile?

Authors:  Pietro Addeo; Elie Oussoultzoglou; Pascal Fuchshuber; Edoardo Rosso; Cinzia Nobili; Regis Souche; Daniel Jaeck; Philippe Bachellier
Journal:  World J Surg       Date:  2013-03       Impact factor: 3.352

8.  Novel technique for biliary reconstruction using an isolated gastric tube with a vascularized pedicle: a live animal experimental study and the first clinical case.

Authors:  Ashraf A Helmy; Mostafa A Hamad; Ahmed M Aly; Tahra Sherif; Mostafa Hashem; Dalia Ah El-Sers; Mohammad Semieka
Journal:  Ann Surg Innov Res       Date:  2011-10-10

9.  Choledochoscopic high-frequency needle-knife electrotomy for treatment of anastomotic strictures after Roux-en-Y hepaticojejunostomy.

Authors:  Yu-Long Yang; Cheng Zhang; Ping Wu; Yue-Feng Ma; Jing-Yi Li; Hong-Wei Zhang; Li-Jun Shi; Mei-Ju Lin; Ying Yu
Journal:  BMC Gastroenterol       Date:  2016-05-06       Impact factor: 3.067

10.  Tamoxifen decreases the myofibroblast count in the healing bile duct tissue of pigs.

Authors:  Orlando Hiroshi Kiono Siqueira; Benedito Herani Filho; Rafael Erthal de Paula; Fábio Otero Ascoli; Antonio Cláudio Lucas da Nóbrega; Angela Cristina Gouvêa Carvalho; Andréa Rodrigues Cordovil Pires; Nicolle Cavalcante Gaglionone; Karin Soares Gonçalves Cunha; José Mauro Granjeiro
Journal:  Clinics (Sao Paulo)       Date:  2013-01       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.